The Economic Times

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer therapy. A subgroup taking the drug without stabilizers showed a nominal benefit. This setback impacts a projected two billion dollar sales opportunity.